Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
Initial marketing authorisation applicationsThe Committee for Medicinal Products for Human Use (CHMP) gave positive opinions recommending the granting of marketing authorisations for Januvia (sitagliptin) and Xelevia (sitagliptin), from Merck Sharp & Dohme. Both products are intended for the treatment of type-II diabetes mellitus in combination with either metformin or, in certain patients, a PPARg agonist (i.e.
India's health biotech firms are emerging as a major global player, with growing means and know-how to produce innovative as well as generic drugs and vaccines at costs small relative to those of giant Western firms, according to ground-breaking Canadian research published April 9.The budding of an innovative Indian biotech sector holds major implications for the global industry and for improving both health and prosperity in the developing world.